Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Core Viewpoint - Revvity, Inc. has announced a definitive agreement to acquire ACD/Labs, enhancing its capabilities in research informatics and expanding its solutions in development and manufacturing [1][2][3] Company Overview - Revvity, Inc. is a provider of health science solutions, technologies, and services, focusing on workflows from discovery to development [8] - The company reported revenue exceeding $2.7 billion in 2024 and employs approximately 11,000 people, serving customers in over 160 countries [9] Acquisition Details - The acquisition of ACD/Labs aims to deepen Revvity Signals' presence in research informatics and strengthen its ability to accelerate scientific innovation [1][3] - ACD/Labs specializes in scientific software solutions that support analytical characterization and molecular design in pharmaceutical and material sciences [2][10] Strategic Benefits - The integration of ACD/Labs' technologies into Revvity Signals will create a unified SaaS environment, connecting molecular design, analytical science, and manufacturing quality control [4][3] - This acquisition is expected to provide comprehensive support across the scientific workflow, enhancing the ability of scientists to manage and act on complex data [3][4] Product Offerings - ACD/Labs offers industry-leading tools such as the Spectrus® Platform for advanced spectral analysis and the Percepta® Platform for AI-driven molecular property prediction [6] - Other specialized applications include Katalyst D2D® for high-throughput experimentation and Luminata® for pharmaceutical chemistry decision support [6]